Skip to content
Inciteful Med

Looking Ahead: Prognosis & Life with Behçet’s

Last updated:

The long-term outlook for Behçet's disease has improved significantly with modern biologic therapies. While men, younger patients, and those with the HLA-B51 gene face higher risks for complications, the disease often "burns out" and becomes less severe as patients get older.

Key Takeaways

  • • Modern biologic therapies have dramatically improved the long-term outlook and life expectancy for Behçet's disease patients.
  • • Men and patients who develop their first symptoms before age 25 typically have a higher risk for a more severe disease course.
  • • Carrying the HLA-B51 gene marker is strongly linked to an increased risk of developing eye disease or neurological complications.
  • • For many patients, Behçet's disease follows a burn out pattern, becoming less severe and less frequent as they age.
  • • Managing the psychological impact, including anxiety and depression, is a critical component of living with Behçet's disease.

While a diagnosis of Behçet’s disease is a lifelong journey, it is important to know that the outlook for patients has improved dramatically over the last two decades. With the introduction of biologic therapies, many of the most serious risks associated with the disease—such as permanent vision loss or severe vascular damage—are now highly manageable [1][2].

Understanding Your Risk Profile

Doctors look at several key factors to understand how the disease might behave over time. This is called risk stratification, and it helps your team decide how aggressive your treatment needs to be [3].

  • Gender: Historically, men tend to experience a more severe disease course, with a higher frequency of ocular and vascular complications [4][3].
  • Age of Onset: Patients who first develop symptoms at a younger age (especially before age 25) are often at a higher risk for more aggressive organ involvement [3][5].
  • Genetics (HLA-B51): Carrying the HLA-B51 gene marker is the strongest known risk factor for the disease [6]. In many patients, this marker is associated with a higher risk of developing eye disease (uveitis) or neurological symptoms [7][8].

Morbidity and Mortality: What We Monitor

The primary goal of monitoring is to prevent complications that lead to long-term illness (morbidity) or shortened life expectancy (mortality).

  • Leading Risks: The most serious complications involve the large blood vessels (such as aneurysms) and the central nervous system (Neuro-Behçet’s) [9][10].
  • Modern Success: While these risks sound frightening, the leading cause of mortality in modern medicine is often the absence of adequate treatment. Patients who are managed by a multidisciplinary team and stay on their maintenance medications generally have a positive long-term outlook [11][12].

The Emotional Landscape: Anxiety and Quality of Life

Living with a chronic, relapsing disease takes a significant psychological toll. It is very common for Behçet’s patients to experience higher levels of anxiety and depression compared to the general population [13][14].

  • Scan Anxiety: It is normal to feel a spike in anxiety before a scheduled MRI, CT scan, or eye exam. This “waiting period” can be just as taxing as the physical symptoms themselves [15].
  • Impact on Life: Interestingly, studies show that even patients with “minor” symptoms (like mouth ulcers) can experience a significant impact on their quality of life due to daily pain and unpredictability [16].
  • Mental Health Support: Connecting with a therapist or joining a rare disease support group can be incredibly beneficial. You don’t have to carry the emotional weight of this diagnosis alone [13].

The Long-Term Outlook

For many, Behçet’s follows a “burn out” pattern, where the frequency and severity of flares often decrease as a person gets older [17]. The goal of your care team is to “bridge” you through the more active years of the disease while protecting your organs from damage [18][1].

Factor Higher Risk Profile Lower Risk Profile
Gender Male [4] Female [16]
Age at First Symptom Under 25 years [3] Over 40 years [17]
HLA-B51 Status Positive [7] Negative [19]
Treatment Response Refractory (resistant) [1] Responsive to first-line agents [20]

Important Note: These are general patterns, not destinies. Every patient’s experience is different, and modern medicine allows for highly personalized plans that account for your specific risk factors [21]. You can navigate back to the Home Page to review any other sections.

Frequently Asked Questions

Does Behçet's disease affect life expectancy?
With modern biologic therapies and proper management, the long-term outlook for Behçet's disease is generally positive. The primary risks to life expectancy come from untreated, severe complications involving the central nervous system or large blood vessels, which are now highly manageable.
What is the long-term prognosis for Behçet's disease?
For many patients, the disease follows a "burn out" pattern, where the frequency and severity of symptom flares decrease as they get older. The main goal of treatment is to protect your organs from damage during the more active, early years of the disease.
Who is at the highest risk for severe Behçet's disease complications?
Men, individuals who develop their first symptoms before age 25, and those carrying the HLA-B51 gene marker typically face a higher risk for aggressive organ involvement. Your doctor will use these factors to create a personalized, risk-stratified treatment plan.
How does my HLA-B51 status affect my prognosis?
Carrying the HLA-B51 gene is the strongest known genetic risk factor for the disease. If you test positive for this marker, you may have a higher risk of developing eye disease, such as uveitis, or neurological symptoms over time.
Is it normal to experience anxiety and depression with Behçet's disease?
Living with a chronic and unpredictable condition takes a significant psychological toll. It is very common to experience anxiety and depression, including "scan anxiety" before medical tests. Seeking support from a therapist or a rare disease support group is highly recommended.

Questions for Your Doctor

  • • Based on my age of onset and gender, how would you classify my 'risk profile' for severe organ involvement?
  • • Does my HLA-B51 status make me more likely to develop ocular or neurological symptoms in the future?
  • • If my inflammation markers (ESR/CRP) remain low, does that mean my risk of major organ damage is also low?
  • • Can you recommend a mental health professional who is familiar with the psychological impact of chronic, relapsing autoimmune diseases?

Questions for You

  • • How do I feel about my long-term outlook, and am I experiencing 'scan anxiety' before my follow-up appointments?
  • • Am I being honest with my care team about 'subtle' symptoms, like changes in my mood, memory, or sleep patterns?
  • • What are my top priorities for my quality of life (e.g., career, travel, family), and is my current treatment plan supporting those goals?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Adamantiades-Behçet's disease therapy: current treatment options and recommendations with regard to the COVID-19 pandemic.

    Trevisini S, Trevisan G, Zalaudek I, Bonin S

    Dermatologic therapy 2022; (35(3)):e15286 doi:10.1111/dth.15286.

    PMID: 34962035
  2. 2

    [Uveitis in Behçet's Syndrome in Germany - Prognosis During Current Therapy].

    Stübiger N, Deuter C, Doycheva D

    Klinische Monatsblatter fur Augenheilkunde 2020; (237(5)):591-598 doi:10.1055/a-1140-3295.

    PMID: 32434242
  3. 3

    Update on the epidemiology, risk factors and disease outcomes of Behçet's disease.

    Akkoç N

    Best practice & research. Clinical rheumatology 2018; (32(2)):261-270 doi:10.1016/j.berh.2018.08.010.

    PMID: 30527431
  4. 4

    Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry.

    Sota J, Ragab G, AlMaglouth I, et al.

    Joint bone spine 2025; (92(2)):105819 doi:10.1016/j.jbspin.2024.105819.

    PMID: 39549971
  5. 5

    High levels of endothelial progenitor cells and circulating endothelial cells in patients with Behçet's disease and their relationship to disease activity.

    Arica DA, Akşan B, Örem A, et al.

    Anais brasileiros de dermatologia 2019; (94(3)):320-326 doi:10.1590/abd1806-4841.20198169.

    PMID: 31365661
  6. 6

    Behçet's disease: New insights into pathophysiology, clinical features and treatment options.

    Greco A, De Virgilio A, Ralli M, et al.

    Autoimmunity reviews 2018; (17(6)):567-575 doi:10.1016/j.autrev.2017.12.006.

    PMID: 29631062
  7. 7

    HLA-B51 Impact on Clinical Symptoms in Behcet's Disease.

    Pamukcu M, Duran TI, Demirag MD

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2022; (32(7)):904-908 doi:10.29271/jcpsp.2022.07.904.

    PMID: 35795941
  8. 8

    Frequency of HLA-B5, HLA-B51 and HLA-B27 in patients with idiopathic uveitis and Behçet's disease: a case-control study.

    Shenavandeh S, Jahanshahi KA, Aflaki E, Tavassoli A

    Reumatologia 2018; (56(2)):67-72 doi:10.5114/reum.2018.75516.

    PMID: 29853720
  9. 9

    Pulmonary artery thrombosis as the first presentation of Behçet's syndrome: a case report and review of the literature.

    Alakkas Z, Kazi W, Mattar M, et al.

    Journal of medical case reports 2021; (15(1)):322 doi:10.1186/s13256-021-02931-1.

    PMID: 34154640
  10. 10

    Pulmonary Artery Aneurysm in Behcet Disease: Medical, Endovascular or Surgical Intervention.

    Samreen I, Darji P, Genobaga S, et al.

    Cureus 2023; (15(11)):e49368 doi:10.7759/cureus.49368.

    PMID: 38146562
  11. 11

    Widespread venous thrombosis: Unveiling a complex case of Behçet's disease with a literature perspective.

    Liu B, Tan C

    Open medicine (Warsaw, Poland) 2025; (20(1)):20251199 doi:10.1515/med-2025-1199.

    PMID: 40823180
  12. 12

    Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet's syndrome: case series and literature review.

    Liu J, Yan D, Wang Z, et al.

    Therapeutic advances in musculoskeletal disease 2020; (12()):1759720X20971908 doi:10.1177/1759720X20971908.

    PMID: 33240406
  13. 13

    An evaluation of depression, anxiety and fatigue in patients with Behçet's disease.

    Can Sandikci S, Colak S, Omma A, Enecik ME

    International journal of rheumatic diseases 2019; (22(6)):974-979 doi:10.1111/1756-185X.13411.

    PMID: 30398004
  14. 14

    Sexual Dysfunction in Male Patients With Behçet's Disease.

    Yıldız M, Batmaz Í, Sula B, et al.

    Acta reumatologica portuguesa 2016; (41(1)):56-61.

    PMID: 27115108
  15. 15

    Relationship between dermatological quality of life, disease activity, depression, and anxiety levels in Behçet's syndrome: a structural equation modelling approach.

    Karacan Y, Akkus Y, Kasap K, Unlu K

    Psychology, health & medicine 2025; 1-15 doi:10.1080/13548506.2025.2565518.

    PMID: 41004688
  16. 16

    Impact of disease activity on health related quality of life in patients with Behçet's disease: A cross-sectional study.

    Gorial FI, Jabbar MA

    Annals of medicine and surgery (2012) 2020; (54()):43-46 doi:10.1016/j.amsu.2020.03.010.

    PMID: 32368339
  17. 17

    Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet's disease: a retrospective observational study.

    Kirino Y, Ideguchi H, Takeno M, et al.

    Arthritis research & therapy 2016; (18(1)):217 doi:10.1186/s13075-016-1115-x.

    PMID: 27716399
  18. 18

    Management of patients with Behçet's disease during the COVID-19 pandemic.

    Dursun R, Temiz SA, Özer İ, et al.

    Dermatologic therapy 2020; (33(6)):e14063 doi:10.1111/dth.14063.

    PMID: 32710599
  19. 19

    Behçet's Disease In Children And Adults Of Sub-Saharan Ancestry: A Systematic Review And Meta-Analysis.

    Suzon B, Felix A, Louis-Sidney F, et al.

    Clinical reviews in allergy & immunology 2025; (68(1)):81 doi:10.1007/s12016-025-09085-8.

    PMID: 40810771
  20. 20

    Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.

    Hatemi G, Mahr A, Takeno M, et al.

    RMD open 2022; (8(2)) doi:10.1136/rmdopen-2022-002235.

    PMID: 35798511
  21. 21

    Promoting patients' empowerment in rheumatic diseases: the perspective of the International Society of Behçet's Disease Working Group on Patient Empowerment, Adherence to Therapy and Patients' Education.

    Di Cianni F, Marinello D, Altenburg A, et al.

    Clinical and experimental rheumatology 2025; (43(10)):1810-1815 doi:10.55563/clinexprheumatol/rk42aa.

    PMID: 40924663

This page discusses Behçet's disease prognosis for educational purposes only and does not replace professional medical advice. Always consult your healthcare provider to discuss your specific risk profile and outlook.

Stay up to date

Get notified when new research about Behçet disease is published.

No spam. Unsubscribe anytime.